Hybrid Closed-Loop Therapy in Adults With Type 1 Diabetes and Above-Target HbA1c : A Real-world Observational Study
© 2023 by the American Diabetes Association..
OBJECTIVE: We explored longitudinal changes associated with switching to hybrid closed-loop (HCL) insulin delivery systems in adults with type 1 diabetes and elevated HbA1c levels despite the use of intermittently scanned continuous glucose monitoring (isCGM) and insulin pump therapy.
RESEARCH DESIGN AND METHODS: We undertook a pragmatic, preplanned observational study of participants included in the National Health Service England closed-loop pilot. Adults using isCGM and insulin pump across 31 diabetes centers in England with an HbA1c ≥8.5% who were willing to commence HCL therapy were included. Outcomes included change in HbA1c, sensor glucometrics, diabetes distress score, Gold score (hypoglycemia awareness), acute event rates, and user opinion of HCL.
RESULTS: In total, 570 HCL users were included (median age 40 [IQR 29-50] years, 67% female, and 85% White). Mean baseline HbA1c was 9.4 ± 0.9% (78.9 ± 9.1 mmol/mol) with a median follow-up of 5.1 (IQR 3.9-6.6) months. Of 520 users continuing HCL at follow-up, mean adjusted HbA1c reduced by 1.7% (95% CI 1.5, 1.8; P < 0.0001) (18.1 mmol/mol [95% CI 16.6, 19.6]; P < 0.0001). Time in range (70-180 mg/dL) increased from 34.2 to 61.9% (P < 0.001). Individuals with HbA1c of ≤58 mmol/mol rose from 0 to 39.4% (P < 0.0001), and those achieving ≥70% glucose time in range and <4% time below range increased from 0.8 to 28.2% (P < 0.0001). Almost all participants rated HCL therapy as having a positive impact on quality of life (94.7% [540 of 570]).
CONCLUSIONS: Use of HCL is associated with improvements in HbA1c, time in range, hypoglycemia, and diabetes-related distress and quality of life in people with type 1 diabetes in the real world.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Diabetes care - 46(2023), 10 vom: 01. Okt., Seite 1831-1838 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Crabtree, Thomas S J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Blood Glucose |
|---|
| Anmerkungen: |
Date Completed 22.09.2023 Date Revised 25.09.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2337/dc23-0635 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36066220X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36066220X | ||
| 003 | DE-627 | ||
| 005 | 20231226083504.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2337/dc23-0635 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1202.xml |
| 035 | |a (DE-627)NLM36066220X | ||
| 035 | |a (NLM)37566697 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Crabtree, Thomas S J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hybrid Closed-Loop Therapy in Adults With Type 1 Diabetes and Above-Target HbA1c |b A Real-world Observational Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.09.2023 | ||
| 500 | |a Date Revised 25.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 by the American Diabetes Association. | ||
| 520 | |a OBJECTIVE: We explored longitudinal changes associated with switching to hybrid closed-loop (HCL) insulin delivery systems in adults with type 1 diabetes and elevated HbA1c levels despite the use of intermittently scanned continuous glucose monitoring (isCGM) and insulin pump therapy | ||
| 520 | |a RESEARCH DESIGN AND METHODS: We undertook a pragmatic, preplanned observational study of participants included in the National Health Service England closed-loop pilot. Adults using isCGM and insulin pump across 31 diabetes centers in England with an HbA1c ≥8.5% who were willing to commence HCL therapy were included. Outcomes included change in HbA1c, sensor glucometrics, diabetes distress score, Gold score (hypoglycemia awareness), acute event rates, and user opinion of HCL | ||
| 520 | |a RESULTS: In total, 570 HCL users were included (median age 40 [IQR 29-50] years, 67% female, and 85% White). Mean baseline HbA1c was 9.4 ± 0.9% (78.9 ± 9.1 mmol/mol) with a median follow-up of 5.1 (IQR 3.9-6.6) months. Of 520 users continuing HCL at follow-up, mean adjusted HbA1c reduced by 1.7% (95% CI 1.5, 1.8; P < 0.0001) (18.1 mmol/mol [95% CI 16.6, 19.6]; P < 0.0001). Time in range (70-180 mg/dL) increased from 34.2 to 61.9% (P < 0.001). Individuals with HbA1c of ≤58 mmol/mol rose from 0 to 39.4% (P < 0.0001), and those achieving ≥70% glucose time in range and <4% time below range increased from 0.8 to 28.2% (P < 0.0001). Almost all participants rated HCL therapy as having a positive impact on quality of life (94.7% [540 of 570]) | ||
| 520 | |a CONCLUSIONS: Use of HCL is associated with improvements in HbA1c, time in range, hypoglycemia, and diabetes-related distress and quality of life in people with type 1 diabetes in the real world | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Glycated Hemoglobin |2 NLM | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Insulin |2 NLM | |
| 700 | 1 | |a Griffin, Tomás P |e verfasserin |4 aut | |
| 700 | 1 | |a Yap, Yew W |e verfasserin |4 aut | |
| 700 | 1 | |a Narendran, Parth |e verfasserin |4 aut | |
| 700 | 1 | |a Gallen, Geraldine |e verfasserin |4 aut | |
| 700 | 1 | |a Furlong, Niall |e verfasserin |4 aut | |
| 700 | 1 | |a Cranston, Iain |e verfasserin |4 aut | |
| 700 | 1 | |a Chakera, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Philbey, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a Karamat, Muhammad Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Saraf, Sanjay |e verfasserin |4 aut | |
| 700 | 1 | |a Kamaruddin, Shafie |e verfasserin |4 aut | |
| 700 | 1 | |a Gurnell, Eleanor |e verfasserin |4 aut | |
| 700 | 1 | |a Chapman, Alyson |e verfasserin |4 aut | |
| 700 | 1 | |a Hussain, Sufyan |e verfasserin |4 aut | |
| 700 | 1 | |a Elliott, Jackie |e verfasserin |4 aut | |
| 700 | 1 | |a Leelarathna, Lalantha |e verfasserin |4 aut | |
| 700 | 1 | |a Ryder, Robert E J |e verfasserin |4 aut | |
| 700 | 1 | |a Hammond, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Lumb, Alistair |e verfasserin |4 aut | |
| 700 | 1 | |a Choudhary, Pratik |e verfasserin |4 aut | |
| 700 | 1 | |a Wilmot, Emma G |e verfasserin |4 aut | |
| 700 | 0 | |a ABCD Closed-Loop Audit Contributors |e verfasserin |4 aut | |
| 700 | 1 | |a Evans, Mark |e investigator |4 oth | |
| 700 | 1 | |a Gurnell, Eleanor |e investigator |4 oth | |
| 700 | 1 | |a Hartnell, Sara |e investigator |4 oth | |
| 700 | 1 | |a Davenport, Katy |e investigator |4 oth | |
| 700 | 1 | |a O'Reilly, Iona |e investigator |4 oth | |
| 700 | 1 | |a Brown, Helen |e investigator |4 oth | |
| 700 | 1 | |a Kamaruddin, Shafie |e investigator |4 oth | |
| 700 | 1 | |a Pickering, Sharon |e investigator |4 oth | |
| 700 | 1 | |a Abouglia, Kamal |e investigator |4 oth | |
| 700 | 1 | |a Wadham, Claire |e investigator |4 oth | |
| 700 | 1 | |a Rayman, Gerry |e investigator |4 oth | |
| 700 | 1 | |a Hussain, Sufyan |e investigator |4 oth | |
| 700 | 1 | |a Brackenridge, Anna |e investigator |4 oth | |
| 700 | 1 | |a Pender, Siobhan |e investigator |4 oth | |
| 700 | 1 | |a Atkinson, Rosarie |e investigator |4 oth | |
| 700 | 1 | |a Bahadur, Melanie |e investigator |4 oth | |
| 700 | 1 | |a Eid, Hatem |e investigator |4 oth | |
| 700 | 1 | |a Carling, Janet |e investigator |4 oth | |
| 700 | 1 | |a Oldfield, Linzi |e investigator |4 oth | |
| 700 | 1 | |a Philbey, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Hammond, Peter |e investigator |4 oth | |
| 700 | 1 | |a Haywood, Sean |e investigator |4 oth | |
| 700 | 1 | |a Gallen, Geraldine |e investigator |4 oth | |
| 700 | 1 | |a Rodgers, Helen |e investigator |4 oth | |
| 700 | 1 | |a Lovie, Kaylee |e investigator |4 oth | |
| 700 | 1 | |a Whight, Emma |e investigator |4 oth | |
| 700 | 1 | |a Nobel-Bell, Georgia |e investigator |4 oth | |
| 700 | 1 | |a Harris, Sophie |e investigator |4 oth | |
| 700 | 1 | |a Cartwright, Anne |e investigator |4 oth | |
| 700 | 1 | |a Garnett, Ian |e investigator |4 oth | |
| 700 | 1 | |a Harvey, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a McCulloch, Frances |e investigator |4 oth | |
| 700 | 1 | |a Yap, Yew Wen |e investigator |4 oth | |
| 700 | 1 | |a Weston, Philip |e investigator |4 oth | |
| 700 | 1 | |a Chapman, Alyson |e investigator |4 oth | |
| 700 | 1 | |a Findlow, Lynne |e investigator |4 oth | |
| 700 | 1 | |a Leelarathna, Lalantha |e investigator |4 oth | |
| 700 | 1 | |a Ohol, Sheetal |e investigator |4 oth | |
| 700 | 1 | |a Thabit, Hood |e investigator |4 oth | |
| 700 | 1 | |a Urwin, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Cowlam, Darron |e investigator |4 oth | |
| 700 | 1 | |a Thomas, Sonia |e investigator |4 oth | |
| 700 | 1 | |a Hyland, Emma |e investigator |4 oth | |
| 700 | 1 | |a Yearsley, Zoey |e investigator |4 oth | |
| 700 | 1 | |a Schofield, Johnathan |e investigator |4 oth | |
| 700 | 1 | |a Soar, Clare |e investigator |4 oth | |
| 700 | 1 | |a Fenn, Laura |e investigator |4 oth | |
| 700 | 1 | |a Mendis, Budd |e investigator |4 oth | |
| 700 | 1 | |a Htike, Zin Zin |e investigator |4 oth | |
| 700 | 1 | |a Cheyne, Elizabeth |e investigator |4 oth | |
| 700 | 1 | |a Emsley, Julie |e investigator |4 oth | |
| 700 | 1 | |a Jones, Elisabeth |e investigator |4 oth | |
| 700 | 1 | |a Parfitt, Vernon |e investigator |4 oth | |
| 700 | 1 | |a Sawyer, Lynn |e investigator |4 oth | |
| 700 | 1 | |a Colosimo, Santo |e investigator |4 oth | |
| 700 | 1 | |a Apsara, Shani |e investigator |4 oth | |
| 700 | 1 | |a Mathara Diddhenipothage, Dilrukshi |e investigator |4 oth | |
| 700 | 1 | |a Lumb, Alistar |e investigator |4 oth | |
| 700 | 1 | |a Hards, Katie |e investigator |4 oth | |
| 700 | 1 | |a Edohen, Florence |e investigator |4 oth | |
| 700 | 1 | |a Beaden, Sue |e investigator |4 oth | |
| 700 | 1 | |a Cranston, Iain |e investigator |4 oth | |
| 700 | 1 | |a Taylor, Julie |e investigator |4 oth | |
| 700 | 1 | |a Skinner, Lisa |e investigator |4 oth | |
| 700 | 1 | |a Bawlchhim, Zosanglura |e investigator |4 oth | |
| 700 | 1 | |a Tuthill, Bev |e investigator |4 oth | |
| 700 | 1 | |a Cull, Melissa Louise |e investigator |4 oth | |
| 700 | 1 | |a Ryder, Robert E J |e investigator |4 oth | |
| 700 | 1 | |a Mitchell, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Rimell, Jill |e investigator |4 oth | |
| 700 | 1 | |a Foley, Clare |e investigator |4 oth | |
| 700 | 1 | |a Gianfrancesco, Carla |e investigator |4 oth | |
| 700 | 1 | |a Elliott, Jackie |e investigator |4 oth | |
| 700 | 1 | |a Butter, Sally |e investigator |4 oth | |
| 700 | 1 | |a Carrieri, Giorgio |e investigator |4 oth | |
| 700 | 1 | |a Douek, Isy |e investigator |4 oth | |
| 700 | 1 | |a King, Rhodri |e investigator |4 oth | |
| 700 | 1 | |a Lambert, Paul |e investigator |4 oth | |
| 700 | 1 | |a Lionetti, Paula |e investigator |4 oth | |
| 700 | 1 | |a Cardwell, Janet |e investigator |4 oth | |
| 700 | 1 | |a Furlong, Niall |e investigator |4 oth | |
| 700 | 1 | |a Keigan, Suzanne |e investigator |4 oth | |
| 700 | 1 | |a Milne, Rachael |e investigator |4 oth | |
| 700 | 1 | |a Wilkinson, Philomena |e investigator |4 oth | |
| 700 | 1 | |a Ashton-Cleary, Siobhan |e investigator |4 oth | |
| 700 | 1 | |a White, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Anthony, Karen |e investigator |4 oth | |
| 700 | 1 | |a Ribul Mazzola, Stefania |e investigator |4 oth | |
| 700 | 1 | |a Sweeney, Stephanie |e investigator |4 oth | |
| 700 | 1 | |a Narendran, Parth |e investigator |4 oth | |
| 700 | 1 | |a Karamat, Ali |e investigator |4 oth | |
| 700 | 1 | |a Saraf, Sanjay |e investigator |4 oth | |
| 700 | 1 | |a Hudson, Barbara |e investigator |4 oth | |
| 700 | 1 | |a Li, Manyee |e investigator |4 oth | |
| 700 | 1 | |a Skelding, Rebecca |e investigator |4 oth | |
| 700 | 1 | |a Williams, Lisa |e investigator |4 oth | |
| 700 | 1 | |a Bartha, Karen |e investigator |4 oth | |
| 700 | 1 | |a Jesson, Anna-Marie |e investigator |4 oth | |
| 700 | 1 | |a Grandy, Lynn |e investigator |4 oth | |
| 700 | 1 | |a Brewer, Deborah |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes care |d 1979 |g 46(2023), 10 vom: 01. Okt., Seite 1831-1838 |w (DE-627)NLM00042983X |x 1935-5548 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2023 |g number:10 |g day:01 |g month:10 |g pages:1831-1838 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2337/dc23-0635 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2023 |e 10 |b 01 |c 10 |h 1831-1838 | ||